(Q26800254)

English

Insulin degludec results in lower rates of nocturnal hypoglycaemia and fasting plasma glucose vs. insulin glargine: A meta-analysis of seven clinical trials

scientific article

In more languages

Statements

scholarly article

0 references

1 reference

based on heuristic

inferred from title

1 reference

Europe PubMed Central

Insulin degludec results in lower rates of nocturnal hypoglycaemia and fasting plasma glucose vs. insulin glargine: A meta-analysis of seven clinical trials (English)

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

insulin glargine

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

D Russell-Jones

1

0 references

M-A Gall

2

0 references

M Niemeyer

3

0 references

M Diamant

4

0 references

S Del Prato

5

0 references

language of work or name

0 references

publication date

October 2015

0 references

Nutrition, Metabolism, and Cardiovascular Diseases

0 references

25

0 references

10

0 references

898-905

0 references

Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin.

1 reference

https://api.crossref.org/works/10.1016%2FJ.NUMECD.2015.06.005

7 January 2021

based on heuristic

inferred from DOI database lookup

Insulin degludec versus insulin glargine in type 1 and type 2 diabetes mellitus: a meta-analysis of endpoints in phase 3a trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.NUMECD.2015.06.005

7 January 2021

based on heuristic

inferred from DOI database lookup

Insulin degludec and insulin degludec/insulin aspart: a review of their use in the management of diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FJ.NUMECD.2015.06.005

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical and socio-economic correlates of quality of life and treatment satisfaction in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FJ.NUMECD.2015.06.005

7 January 2021

based on heuristic

inferred from DOI database lookup

Lower fasting blood glucose, glucose variability and nocturnal hypoglycaemia with glargine vs NPH basal insulin in subjects with Type 1 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.NUMECD.2015.06.005

7 January 2021

based on heuristic

inferred from DOI database lookup

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority tria

1 reference

https://api.crossref.org/works/10.1016%2FJ.NUMECD.2015.06.005

7 January 2021

based on heuristic

inferred from DOI database lookup

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority tria

1 reference

https://api.crossref.org/works/10.1016%2FJ.NUMECD.2015.06.005

7 January 2021

based on heuristic

inferred from DOI database lookup

Addressing barriers to initiation of insulin in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FJ.NUMECD.2015.06.005

7 January 2021

based on heuristic

inferred from DOI database lookup

Ligand-controlled assembly of hexamers, dihexamers, and linear multihexamer structures by the engineered acylated insulin degludec

1 reference

https://api.crossref.org/works/10.1016%2FJ.NUMECD.2015.06.005

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical experience with insulin glargine in type 1 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FJ.NUMECD.2015.06.005

7 January 2021

based on heuristic

inferred from DOI database lookup

Self-reported non-severe hypoglycaemic events in Europe

1 reference

https://api.crossref.org/works/10.1016%2FJ.NUMECD.2015.06.005

7 January 2021

based on heuristic

inferred from DOI database lookup

Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.NUMECD.2015.06.005

7 January 2021

based on heuristic

inferred from DOI database lookup

A comparison of health-related quality of life (health utility) between insulin degludec and insulin glargine: a meta-analysis of phase 3 trials.

1 reference

https://api.crossref.org/works/10.1016%2FJ.NUMECD.2015.06.005

7 January 2021

based on heuristic

inferred from DOI database lookup

Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATE study

1 reference

https://api.crossref.org/works/10.1016%2FJ.NUMECD.2015.06.005

7 January 2021

based on heuristic

inferred from DOI database lookup

Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.NUMECD.2015.06.005

7 January 2021

based on heuristic

inferred from DOI database lookup

Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FJ.NUMECD.2015.06.005

7 January 2021

based on heuristic

inferred from DOI database lookup

Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study

1 reference

https://api.crossref.org/works/10.1016%2FJ.NUMECD.2015.06.005

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and efficacy of insulin detemir in clinical practice: 14-week follow-up data from type 1 and type 2 diabetes patients in the PREDICTIVE European cohort

1 reference

https://api.crossref.org/works/10.1016%2FJ.NUMECD.2015.06.005

7 January 2021

based on heuristic

inferred from DOI database lookup

Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir

1 reference

https://api.crossref.org/works/10.1016%2FJ.NUMECD.2015.06.005

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension

1 reference

https://api.crossref.org/works/10.1016%2FJ.NUMECD.2015.06.005

7 January 2021

based on heuristic

inferred from DOI database lookup

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

1 reference

https://api.crossref.org/works/10.1016%2FJ.NUMECD.2015.06.005

7 January 2021

based on heuristic

inferred from DOI database lookup

Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long)

1 reference

https://api.crossref.org/works/10.1016%2FJ.NUMECD.2015.06.005

7 January 2021

based on heuristic

inferred from DOI database lookup

The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in i

1 reference

https://api.crossref.org/works/10.1016%2FJ.NUMECD.2015.06.005

7 January 2021

based on heuristic

inferred from DOI database lookup

Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-ta

1 reference

https://api.crossref.org/works/10.1016%2FJ.NUMECD.2015.06.005

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people

1 reference

https://api.crossref.org/works/10.1016%2FJ.NUMECD.2015.06.005

7 January 2021

based on heuristic

inferred from DOI database lookup

Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FJ.NUMECD.2015.06.005

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.NUMECD.2015.06.005

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

release_7rbvu4zffjh55inkoihveq7y4u

1 reference

https://api.fatcat.wiki/v0/release/7rbvu4zffjh55inkoihveq7y4u

24 November 2022

based on heuristic

mapped directly with Wikidata item

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q26800254&oldid=1975760153"